comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
Published 1 year ago • 105 plays • Length 6:38Download video MP4
Download video MP3
Similar videos
-
4:49
car-t vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
2:06
the optimal sequencing of car-t and other immunotherapies in multiple myeloma
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
25:01
what are the four different types of medical device risk analysis?
-
12:24
introduction to different classifications rules for medical device software
-
17:17
cqe series 26: quality indicators in transfusion services
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:55
safety and efficacy of nxc-201, an anti-bcma car-t, in r/r al amyloidosis
-
3:09
an overview of the toxicities associated with immunotherapy in multiple myeloma
-
2:35
inflammatory biomarkers as predictors of car-t efficacy in multiple myeloma
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
56:58
translatable efficacy & safety testing of mab, bispecific, & car t therapies
-
1:14
the car t-cell strategy vs bispecific antibodies
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells